Hims & Hers: KeyBanc's Neutral Stance and Growth Potential

Hims & Hers: Growth Stock or Profitability Puzzle? KeyBanc initiates coverage, highlighting the telehealth giant's expansion potential in sexual health, dermatology, and more, but warns profits may lag behind revenue. Will international markets and new treatments like testosterone and menopause support fuel growth, or will competition and regulations hinder progress? Find out what KeyBanc's $52 price target means for investors.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.